ID   SF172
AC   CVCL_V613
SY   SF-172
DR   BioSample; SAMN10988399
DR   cancercelllines; CVCL_V613
DR   Cell_Model_Passport; SIDM01351
DR   Cosmic; 2516034
DR   DepMap; ACH-000887
DR   PharmacoDB; SF172_1365_2019
DR   Progenetix; CVCL_V613
DR   Wikidata; Q54952895
RX   PubMed=25984343;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Problematic cell line: Probably misidentified/contaminated. Except of a loss of an allele of TH01 the STR profile of SF172 is identical to that of SF763. Furthermore we could not find in the literature any trace of the exact origin of SF172 and, according to a personal communication of Shai A. from the UCSF Biorepository, there is no record of SF172 in their system while SF763 is registered there. The TP53 mutation recorded for SF763 is also identical to the one in SF172.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 24 hours (PubMed=25984343).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Homozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: shRNA library screening.
CC   Genome ancestry: African=75.55%; Native American=0.48%; East Asian, North=4.1%; East Asian, South=0%; South Asian=0%; European, North=7%; European, South=12.87% (PubMed=30894373).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): DepMap
ST   Amelogenin: X
ST   CSF1PO: 9
ST   D13S317: 10,12
ST   D16S539: 10
ST   D18S51: 16
ST   D21S11: 27,30
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 11,12
ST   D8S1179: 13,14
ST   FGA: 22
ST   Penta D: 11,12
ST   Penta E: 5,13
ST   TH01: 8,9
ST   TPOX: 10,11
ST   vWA: 16,17
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6949 ! SF763
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 16
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//